VLS Valneva SE

VALNEVA Declaration of shares and voting rights: September 30, 2025

VALNEVA Declaration of shares and voting rights: September 30, 2025

VALNEVA

Declaration of shares and voting rights

September 30, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: October 6, 2025

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
171,854,856 



ordinary shares with a par value of €0.15 each





187,978,646Transfer into bearer form of 653 shares with double voting rights









Double voting rights granted on 100 ordinary shares





Between September 1 & September 18, 2025









On September 29, 2025





187,854,324

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
06/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Valneva publie ses résultats financiers des neuf premiers mois de 2025...

Valneva publie ses résultats financiers des neuf premiers mois de 2025 et fait un point sur ses activités   Chiffre d’affaires de 127,0 millions d’euros contre 116,6 millions d’euros sur les neuf premiers mois de 2024Trésorerie de 143,5 millions d’euros à fin septembre 2025Flexibilité financière accrue grâce au succès du refinancement de la dette en octobre 20251Poursuite de l’étude de Phase 3 VALOR contre la maladie de Lyme selon le calendrier prédéfiniConfirmations des perspectives financières 20251 Saint-Herblain (France), le 20 novembre 2025 – (Nasdaq: VALN; Euronext Paris: VLA), soc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch